Bit Bio, the new startup which pitches itself as the enter button for the keyboard to the software of life only needed three weeks to raise its latest $41.5 million round of funding.
Originally known as Elpis Biotechnology and named for the Greek goddess of hope, the Cambridge, England-based company was founded by Mark Kotter in 2016 to commercialize technology that can reduce the cost and increase the production capacity for human cell lines. These cells can be used in targeted gene therapies and as a method to accelerate drug discovery at pharmaceutical companies.
The companys goal is to be able to reproduce every human cell type.
Were just at a very crucial time in biology and medicine and the bottleneck that has become really clear is a scalable source of robust human cells, said Kotter. For drug discovery this is important. When you look at failure rates in clinical trials theyre at an all time high thats in direct contradiction to the massive advancements in biotechnology in research and the field.
In the seventeen years since scientists completely mapped the human genome, and eight years since scientists began using the gene editing technology known as CRISPR to edit genetic material, theres been an explosion of treatments based on individual patients genetic material and new drugs developed to more precisely target the mechanisms that pathogens use to spread through organisms.
These treatments and the small molecule drugs being created to stop the spread of pathogens or reduce the effects of disease require significant testing before coming to market and Bit Bios founder thinks his company can both reduce the time to market and offer new treatments for patients.
Its a thesis that had investors like the famous serial biotech entrepreneur, Richard Klausner, who served as the former director of the National Cancer Institute and founder of revolutionary biotech companies like Lyell Immunopharma, Juno, and Grail, leaping at the chance to invest in Bit Bios business, according to Kotter.
Joining Klausner are the famous biotech investment firms Foresite Capital, Blueyard Capital and Arch Venture Partners.
Bit Bio is based on beautiful science. The companys technology has the potential to bring the long-awaited precision and reliability of engineering to the application of stem cells, said Klausner in a statement. Bit Bios approach represents a paradigm shift in biology that will enable a new generation of cell therapies, improving the lives of millions.
Photo: Andrew Brookes/Getty Images
Kotters own path to develop the technology which lies at the heart of Bit Bios business began a decade ago in a laboratory in Cambridge University. It was there that he began research building on the revolutionary discoveries of Shinya Yamanaka, which enabled scientists to transform human adult cells into embryonic stem cells.
What we did is what Yamanaka did. We turned everything upside down. We want to know how each cell is defined and once we know that we can flip the switch, said Kotter. We find out which transcription factors code for a single cell and we turn it on.
Kotter said the technology is like uploading a new program into the embryonic stem cell.
Although the company is still in its early days, it has managed to attract a few key customers and launch a sister company based on the technology. That company, Meatable, is using the same process to make lab-grown pork.
Meatable is the earliest claimant to a commercially viable, patented process for manufacturing meat cells without the need to kill an animal as a prerequisite for cell differentiation and growth.
Other companies have relied on fetal bovine serum or Chinese hamster ovaries to stimulate cell division and production, but Meatablesays it has developed a processwhere it can sample tissue from an animal, revert that tissue to a pluripotent stem cell, then culture that cell sample into muscle and fat to produce the pork products that palates around the world crave.
We know which DNA sequence is responsible for moving an early-stage cell to a muscle cell, says Meatable chief executive Krijn De Nood.
If that sounds similar to Bit Bio, thats because its the same tech just used to make animal instead of human cells.
Image: PASIEKA/SCIENCE PHOTO LIBRARY/Getty Images
If Meatable is one way to commercialize the cell differentiation technology, Bit Bios partnership with the drug development company Charles River Laboratories is another.
We actually do have a revenue generating business side using human cells for research and drug discovery. We have a partnership with Charles River Laboratories the large preclinical contract research organization, Kotter said. That partnership is where we have given early access to our technology to Charles River They have their own usual business clients who want them to help with their drug discovery. The big bottleneck at the moment is access to human cells.
Drug trials fail because the treatments developed either are toxic or dont work in humans. The difference is that most experiments to prove how effective the treatments are rely on animal testing before making the leap to human trials, Kotter said.
The company is also preparing to develop its own cell therapies, according to Kotter. There, the biggest selling point is the increased precision that Bit Bio can bring to precision medicine, said Kotter. If you look at these cell therapies at the moment you get mixed bags of cells. There are some that work and some that have dangerous side effects. We think we can be precise [and] safety is the biggest thing at this point.
The company claims that it can produce cell lines in less than a week with 100 percent purity, versus the mixed bags from other companies cell cultures.
Our moonshot goal is to develop a platform capable of producing every human cell type. This is possible once we understand the genes governing human cell behaviour, which ultimately form the operating system of life, Kotter said in a statement. This will unlock a new generation of cell and tissue therapies for tackling cancer, neurodegenerative disorders and autoimmune diseases and accelerate the development of effective drugs for a range of conditions. The support of leading deep tech and biotech investors will catalyse this unique convergence of biology and engineering.
See original here:
Bit Bios enter button for the keyboard to the software of life nabs the company $41.5 million - TechCrunch
- Genetic Engineering and Its Applications StudyBullet.com - March 9th, 2025
- The Future of Gene-Editing Treatments for Rare Diseases - March 9th, 2025
- Biotechnology & Genetic Engineering: An Overview - Sciencing - March 9th, 2025
- Hoping to revive mammoths, scientists create 'woolly mice' - NPR - March 9th, 2025
- CRISPR Breakthrough Unlocks the Genetic Blueprint for ... - SciTechDaily - March 9th, 2025
- Mice have been genetically engineered to look like mammoths - The Economist - March 9th, 2025
- Gene modification can create bigger, better tomatoes, but should we do it? - Earth.com - March 9th, 2025
- "Colossal woolly mouse" created by scientists in effort to reconstruct the woolly mammoth - CBS News - March 9th, 2025
- Biotech company hoping to revive woolly mammoth, creates woolly mouse: Study - Straight Arrow News - March 9th, 2025
- Colossal Creates the Colossal Woolly Mouse, Showcasing Breakthroughs in Multiplex Genome Editing and Trait Engineering on the Path to a Mammoth -... - March 9th, 2025
- Colossal Biosciences is one step further in quest to bring back the woolly mammoth - Austin American-Statesman - March 9th, 2025
- Biotech Company Creates 'Woolly Mouse' as a Step in Its Quest to Resurrect Woolly Mammoths Through Gene Editing - Smithsonian Magazine - March 9th, 2025
- 'We didn't know they were going to be this cute': Scientists unveil genetically engineered 'woolly mice' - Livescience.com - March 9th, 2025
- These Genetically Engineered Mice Have Thick Woolly Mammoth Hair - ExtremeTech - March 9th, 2025
- Genetically altered mouse to pave way for resurrection of wolly mammoth? - Hindustan Times - March 9th, 2025
- Turning back the aging clock: Billions of dollars are probably being wasted on genetic manipulation techniques that likely wont work - Genetic... - March 9th, 2025
- OF WOOLLY MICE AND MAMMOTHS - Particle - March 9th, 2025
- Woolly mouse unveiled by firm hoping to bring more extinct animals back to life - The National - March 9th, 2025
- How scientists created woolly mice as part of their quest to bring back the woolly mammoth - The Indian Express - March 9th, 2025
- A Woolly What? - Brownstone Research - March 9th, 2025
- $1 Million Awarded to Continue to Develop Genetically Engineered Stem Cell Products to Fight Gastroesophageal Cancer - PR Newswire - February 15th, 2025
- Engineered animals show new way to fight mercury pollution - EurekAlert - February 15th, 2025
- Genetically modified foods: benefits and applications - Meer - February 15th, 2025
- Genetically modified zebrafish and fruit flies munch on mercury to make it less toxic - Yahoo - February 15th, 2025
- Principles of Genetic Engineering - PubMed Central (PMC) - February 7th, 2025
- The next 'big thing' in genetically modified crops: Drought-tolerant and herbicide resistant wheat. Here's what you need to know - Genetic Literacy... - February 7th, 2025
- Genetic engineering and biotechnology: The future of food is here - Yourweather.co.uk - February 7th, 2025
- Scientists Just Achieved a Major Milestone in Creating Synthetic Life - Yahoo! Voices - February 7th, 2025
- Two males give birth to child in incredible science experiment; the baby is now an adult | Mint - Mint - February 7th, 2025
- Genetic Engineering - The Definitive Guide | Biology Dictionary - January 27th, 2025
- Constitutive expression of Cas9 and rapamycin-inducible Cre recombinase facilitates conditional genome editing in Plasmodium berghei - Nature.com - January 27th, 2025
- What is Genetic Engineering? - Baker Institute - January 27th, 2025
- ARCUS breakthrough: An advanced gene editing tool appears to have cured an infant of an early onset metabolic disorder - Genetic Literacy Project - January 27th, 2025
- Your cells are dying. All the time. - Genetic Literacy Project - January 27th, 2025
- How Genetic Modification is Changing the Future of Conservation - MSN - January 27th, 2025
- Researchers genetically engineer yeast to produce healthy fatty acid - University of Alberta - January 27th, 2025
- genetic engineering summary | Britannica - September 13th, 2024
- The great gene editing debate: can it be safe and ethical? - BBC.com - September 13th, 2024
- Anti-biotechnology campaigners embrace classic crops, are suspicious of hybrid varieties and claim genetic modification violates nature. Heres a... - September 13th, 2024
- Will IL-11 Control Extend Human Life One Day? Early Results are Tantalizing - Securities.io - September 13th, 2024
- Viewpoint: As New Zealand edges toward relaxing its ban on gene edited foods, experts weigh in - Genetic Literacy Project - September 13th, 2024
- Farmers in Brazil and Argentina ramp up growing of genetically-modified drought tolerant wheat that can grow in subtropical regions - Genetic Literacy... - September 13th, 2024
- Scientist explains why we'll never have a real Jurassic Park - and people are crestfallen - indy100 - September 13th, 2024
- Genetic engineering techniques - Wikipedia - January 9th, 2024
- 20.3: Genetic Engineering - Biology LibreTexts - January 9th, 2024
- Genetic engineering - DNA Modification, Cloning, Gene Splicing - December 13th, 2023
- Global Gene Editing Market Poised for Significant Growth, Projected to Reach $14.28 Billion by 2027 - EIN News - December 13th, 2023
- Principles of Genetic Engineering - PMC - National Center for ... - May 17th, 2023
- Quitting: A Life Strategy: The Myth of Perseveranceand How the New Science of Giving Up Can Set You Free - Next Big Idea Club Magazine - May 17th, 2023
- 18 Human Genetic Engineering - Clemson University - March 29th, 2023
- Pros and Cons of Genetic Engineering - Benefits and Risks - March 29th, 2023
- How artificial skin is made and its uses, from treating burns to skin cancer - South China Morning Post - March 29th, 2023
- Genetic Engineering - Meaning, Applications, Advantages and Challenges ... - March 13th, 2023
- Revolutionary Specialty Enzymes Transform Industries, Projected to Reach $2.2 Billion by 2031 - Billion-Dollar - EIN News - March 5th, 2023
- Explained: What is genome editing technology and how is it different from GM technology? - The Indian Express - April 2nd, 2022
- Scribe Therapeutics to Participate in Upcoming Goldman Sachs The New Guard: Privates Leading the Disruption in Healthcare Investor Conference - Yahoo... - April 2nd, 2022
- San Antonio Zoo In Discussions on Woolly Mammoth Project - iHeart - April 2nd, 2022
- Xenotransplantation trials will require adjusting expectations, experts say - STAT - April 2nd, 2022
- 5 Interesting Startup Deals You May Have Missed In March: Restoring The Woolly Mammoth, Faux Seafood And Lots Of Bees - Crunchbase News - April 2nd, 2022
- Synlogic to Present Data on Phenylketonuria and Homocystinuria Programs at the Society for ... - KULR-TV - April 2nd, 2022
- The Bay Area food tech industry is creating more than vegan burgers. Heres whats next - San Francisco Chronicle - April 2nd, 2022
- Student Startup Teams to Compete For $110000 Cash Prize Pool in U of A's Heartland Challenge - University of Arkansas Newswire - April 2nd, 2022
- Should we test for differences in allergen content between varieties of crops and animal species? - Open Access Government - April 2nd, 2022
- Genetic Engineering - Courses, Subjects, Eligibility ... - December 22nd, 2021
- Scientists Used CRISPR Gene Editing to Choose the Sex of Mouse Pups - Singularity Hub - December 22nd, 2021
- Report calls for broad public deliberation on releasing gene-edited species in the wild - EurekAlert - December 22nd, 2021
- RNA and DNA Extraction Kit Market Study | Know the Post-Pandemic Scenario of the Industry - BioSpace - December 22nd, 2021
- Opinion: Allow Golden Rice to save lives - pnas.org - December 22nd, 2021
- It's time for an alliance of democracies | TheHill - The Hill - December 22nd, 2021
- Aridis Pharmaceuticals Announces a Pan-Coronavirus Monoclonal Antibody Cocktail That Retains Effectiveness Against the Omicron variant, other COVID-19... - December 22nd, 2021
- 2021: when the link between the climate and biodiversity crises became clear - The Guardian - December 22nd, 2021
- Wuhan lab leak now the most likely cause of Covid pandemic and the truth WILL come out, experts tell MPs... - The US Sun - December 22nd, 2021
- Biotech ETFs That Outperformed Last Week - Yahoo Finance - December 22nd, 2021
- Human genetic enhancement - Wikipedia - October 5th, 2021
- Viewpoint: Part 1 Opposition stirred by anti-GMO advocacy group propaganda fading in the developing world, as more countries embrace crop... - October 5th, 2021
- Amyris Partners with Inscripta to Enhance Development of Sustainable Ingredients Using the Onyx Genome Engineering Platform - WWNY - October 5th, 2021
- Kingdom Supercultures raises $25m to expand Non GMO suite of microbes to unlock new flavors, textures, and functionalities in food & beverage -... - October 5th, 2021
- Fact check: Genetically engineering your salad with the COVID-19 vaccines? We're not there yet. - USA TODAY - October 5th, 2021
- Making the Transition from an Academic to a Biobusiness Entrepreneur - Genetic Engineering & Biotechnology News - October 5th, 2021
- Is The New York Times Finally 'Learning To Love GMOS'? - American Council on Science and Health - October 5th, 2021